Investing in Australian tech stocks

Published 02-OCT-2020 14:45 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Over the past six months, the majority of the workforce has worked from home. Many supported with a significant number of Job Keeper payments.According to a report from ASIC, this has resulted in a large influx of new investors and traders into the stock market.

When we look at what these new entrants have been buying, it has largely been technology stocks with a big uptake in US tech stocks. But is this a wise choice or are many investors simply following the herd?

When talking about technology stocks, invariably most people think of Facebook, Apple, Amazon, Netflix and Google, which are known as FAANG stocks, with many investors holding one or more of these companies. So how do Australian technology companies stack up in comparison to their US counterparts?

In Australia, the technology stocks comprise WiseTech Global, Appen, Altium, Afterpay Touch and Xero, which are otherwise known as WAAAX stocks.

You may be surprised to learn that since 1 January to 30 September 2020, FAANG stocks have returned a gross capital gain of 220.21 per cent, while WAAAX stocks have achieved a return of 264.81 per cent or around 20 per cent better.

While this is only a snapshot in time and is in no way conclusive evidence of one market performing better than the other, what it does highlight is the myth that investing in offshore markets can make you more money. Those new to the market are led to believe that investing in US tech stocks is better than investing in Australian tech stocks, but unfortunately, none of this is true.

The ASX is well regulated and lists some of the world’s best companies: so, while some world markets may outperform our market for short periods, over the long term it not only holds its weight but outperforms nearly all other world markets in terms of return.

As the book, Triumph of the Optimists : 1 01 Years of Global Investment Returns released by Princeton University Press nearly 20 years ago and updated in 2018 reveals, the Australian stock market is in the top three best performing markets in the world with the US market much further down the list.

Based on these facts, you have to question why anyone would want to increase their risk to sacrifice better returns by investing in Australia.

Dale Gillham is Chief Analyst at Wealth Within and international bestselling author of How to Beat the Managed Funds by 20%. He is also author of the award winning book Accelerate Your Wealth—It’s Your Money, Your Choice, which is available in all good bookstores and online at www.wealthwithin.com.au

Your Wealth—It’s Your Money, Your Choice, which is available in all good bookstores and online at www.wealthwithin.com.au.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X